Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
LSD1-IN-25
LSD1-IN-25
Contact us for more batch information
LSD1-IN-25
Catalog No. T74855Cas No. 2911585-60-7
LSD1-IN-25 (Compound 9j) is a potent, selective, and orally active inhibitor of LSD1, exhibiting an IC50 of 46 nM (Ki = 30.3 nM) and capable of inducing apoptosis in cancer cells [1].
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | Inquiry | Backorder | |
| 50 mg | Inquiry | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "LSD1-IN-25"
KDM2A/7A-IN-1
T117482169272-46-0In house
KDM2A/7A-IN-1 is a cell-permeable and selective inhibitor of the histone lysine demethylase KDM2A/7A with potential antitumor activity for the study of duodenal adenomas and ossifying fibromucoid tumors.
- $272
Size
QTY
NCGC00244536
TQ00502003260-55-5
NCGC00244536 (KDM4B Inhibitor B3) is a potent KDM4B inhibitor (IC50: 10 nM).
- $97
Size
QTY
KDM5A-IN-1
T156501905481-36-8
KDM5A-IN-1 is an orally available, potent and selective inhibitor of the pan-histidine lysine demethylase 5 KDM5, inhibiting KDM5A, KDM5B, and KDM5C with IC50 values of 45 nM, 56 nM, and 55 nM, respectively.KDM5A-IN-1 inhibits PC9 H3K4Me3, and may be useful in cancer research.
- $149
Size
QTY
JQKD82
T399892410512-38-6
JQKD82 is a selective inhibitor of KDM5 and increases H3K4me3. JQKD82 can be used in studies about the treatment of multiple myeloma.
- $137
Size
QTY
Procaine hydrochloride
T080251-05-8
Procaine hydrochloride (Novocaine HCl) is the hydrochloride salt form of procaine, a benzoic acid derivative with local anesthetic and antiarrhythmic properties. Procaine binds to and inhibits voltage-gated sodiumchannels, thereby inhibiting the ionic flux required for the initiation and conduction of impulses. In addition, this agent increases electrical excitation threshold, reduces rate of rise of action potential and slows nerve impulse propagation thereby causing loss of sensation.
- $42
Size
QTY
Tranylcypromine hemisulfate
T794213492-01-8
Tranylcypromine hemisulfate (Tranylcypromine Sulfate) is an inhibitor of monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1) with a rapid onset of activity.
- $48
Size
QTY
Vafidemstat
T172111357362-02-7
Vafidemstat (ORY-2001) is a selective, orally active lysyl-histone demethylase (LSD1)/MAO-B inhibitor that crosses the blood-brain barrier for the study of neurological diseases.
- $179
Size
QTY
3-pyridine toxoflavin
T6773832502-20-8
3-pyridine toxoflavin is a potent KDM4C inhibitor, IC50=19nM.
- $195
Size
QTY
Tranylcypromine (2-PCPA) hydrochloride
T10251986-47-6
Tranylcypromine (2-PCPA) hydrochloride (SKF-385 HCl), a Monoamine Oxidase inhibitor, is effective in the treatment of major depression, dysthymic disorder, and atypical depression.
- $39
Size
QTY
GSK-J1
T68471373422-53-7
GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
- $40
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | LSD1-IN-25 (Compound 9j) is a potent, selective, and orally active inhibitor of LSD1, exhibiting an IC50 of 46 nM (Ki = 30.3 nM) and capable of inducing apoptosis in cancer cells [1]. |
| In vitro | LSD1-IN-25 (Compound 9j; 0-20 μM; 72 h) inhibits the proliferation of solid tumor cells [1]. At concentrations of 1-4 μM and a 24-hour exposure, LSD1-IN-25 induces an increase in H3K4me2 levels and inhibits the epithelial-mesenchymal transition (EMT) process in H1650 cells [1]. Additionally, LSD1-IN-25 (1-4 μM; 24 h) induces apoptosis and S-phase arrest in H1650 cells [1]. |
| In vivo | LSD1-IN-25 (Compound 9j; 10 and 20 mg/kg; oral gavage; daily for 21 days) demonstrated antitumor activity in a H1650 cell xenograft mouse model [1]. |
| Molecular Weight | 617.16 |
| Formula | C32H33ClN6O3S |
| Cas No. | 2911585-60-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.